The estimated Net Worth of Robert Charnas is at least $238 mil dollars as of 1 February 2017. Robert Charnas owns over 3,008 units of Puma Biotechnology Inc stock worth over $66,133 and over the last 8 years Robert sold PBYI stock worth over $171,964.
Sign up
Robert Charnas PBYI stock SEC Form 4 insiders trading
Robert has made over 2 trades of the Puma Biotechnology Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Robert sold 3,008 units of PBYI stock worth $95,745 on 1 February 2017.
The largest trade Robert's ever made was selling 3,008 units of Puma Biotechnology Inc stock on 1 February 2017 worth over $95,745. On average, Robert trades about 884 units every 2 days since 2016. As of 1 February 2017 Robert still owns at least 26,453 units of Puma Biotechnology Inc stock.
You can see the complete history of Robert Charnas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Charnas's mailing address?
Robert's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES, CA, 90024.
Insiders trading at Puma Biotechnology Inc
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo, eTroy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
What does Puma Biotechnology Inc do?
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
What does Puma Biotechnology Inc's logo look like?
Complete history of Robert Charnas stock trades at Puma Biotechnology Inc
Puma Biotechnology Inc executives and stock owners
Puma Biotechnology Inc executives and other stock owners filed with the SEC include:
-
Alan H. Auerbach,
Founder, Chairman, Pres, CEO & Sec. -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alan Auerbach,
Chairman of the Board, President, Chief Executive Officer -
Douglas Hunt B.Sc., FRAPS,
Sr. VP of Regulatory Affairs, Medical Writing & Project Management -
Maximo F. Nougues,
CFO & Principal Accounting Officer -
Douglas Hunt,
Senior Vice President, Regulatory Affairs, Medical Writing and Project Management -
Richard Bryce,
Chief Medical and Scientific Officer -
Ann Miller,
Independent Director -
Dr. Richard P. Bryce,
Chief Medical & Scientific Officer -
Maximo Nougues,
Chief Financial Officer -
Hugh O Dowd,
Independent Director -
Jay Moyes,
Lead Independent Director -
Troy Wilson,
Independent Director -
Adrian Senderowicz,
Independent Director -
Michael Miller,
Independent Director -
Mariann Ohanesian,
IR Contact Officer -
Brian Stuglik,
Director -
Dr. Alvin F. Wong,
Chief Scientific Officer -
Charon Spencer Sr.,
VP of HR -
Steven Lo,
Chief Commercial Officer -
Capital Partners Gp, L.L.C....,
-
Robert Charnas,
-
Richard Benton Phillips,
SEE REMARKS -
Charles R Eyler,
SEE REMARKS -
Frank Zavrl,
Director -
Thomas Malley,
Director -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alvin F Wong,
Chief Scientific Officer -
Allison Dorval,
Director -
Alessandra Cesano,
Director